Nanolive hosts this event on “Non-invasive, high content live cell assays to increase translational relevance of in vitro drug development of biologics and small molecules”.
In this webinar, we present the following use-cases of our immuno-oncology and cytotoxicity assays from industry-leading biopharma companies to test toxicity, selectivity, uptake and expression of different targeted therapies.
- Immune cell therapeutics:
- Bispecific antibody screening in a T cell-target cell co-culture (Lightchain Bioscience)
- Drug selectivity and cytotoxicity:
- mRNA expression and cytotoxicity (TrON)
- Drug selectivity in co-cultures: senolytics (dsm-firmenich)
- Measuring particle uptake (bit.bio)
This webinar lasts 20 to 25 minutes.
Read our latest news
Nanolive at the SPS Annual Meeting September 18-20
Joint presentation with Sanofi Nanolive is delighted to invite for you to attend our upcoming joint presentation with Sanofi at the Safety Pharmacology Society (SPS) Annual Meeting in Brussels on September 20, 2023, from 12:30 PM to 1:30 PM in Studio 214. During our...
Nanolive empowers groundbreaking ferroptosis research published in Nature
Congratulations to the Conrad lab for their latest Nature paper 'Phase separation of FSP1 promotes ferroptosis'! This beautiful capture published as part of the paper provides new information about the events leading up to ferroptotic cell death. Using refractive...
New possibilities for potent cancer immunotherapies with Nanolive solutions
We are thrilled to announce a groundbreaking scientific study authored by Mathieu Frechin and Daniel Olive, in collaboration with Aix Marseille Université, ImCheck therapeutics, and Nanolive. Their remarkable research on Vγ9Vδ2 T cells has opened up new possibilities...
